Technological Integration Boosts Patient Engagement & Control in Diabetes: 1st of its kind, evidence-based India centric study showcases groundbreaking results
- A landmark analysis conducted by Roche Diabetes Care including approximately 40,000 people with diabetes living in India, highlights a statistically significant reduction in eHbA1c in Type II Diabetes (T2DM) when the mySugr® application was used in conjunction with a blood glucose meter.
- The average change in glycemia that was documented on the mySugr® application was associated with regular self-monitoring of blood glucose (SMBG) that helped people with diabetes achieve better glycemic control, reduce the incidence of complications and improve their overall quality of life.
- The analysis also highlighted how the use of mHealth platforms, like the mySugr® application, can not only better engage patients in their diabetes management journey, but also retain said engagement which is often challenging for healthcare professionals.
Mumbai, India, 16 Nov 2023: Roche presented a groundbreaking real-world data analysis at the 51st Annual Conference of the Research Society for Study of Diabetes (RSSDI) in Mumbai on the occasion of World Diabetes Day. The presented analysis, conducted for the first time in India, revealed the profound impact of combining regular self-monitoring of blood glucose (SMBG) with the mySugr app on the engagement and glycemic management of people with Type 2 Diabetes (T2DM).
This comprehensive analysis, including almost 40,000 active users with T2DM, focuses on estimated HbA1c (eHbA1c) and Points In Range (PIR), and provides crucial insights into the advantages of utilising technology to enhance diabetes management. The purpose of this analysis was to describe how people with T2DM use the mySugr mobile application and to assess the impact on glycemic management using estimated HbA1c (eHbA1c) and Points In Range (PIR).
The analysis found that integration enhanced patient engagement significantly, and users reported greater frequency of blood glucose monitoring, improved medication adherence, and increased overall awareness of their diabetes care.
Between January 2022 and July 2023, people with T2DM used the mySugr app with 76.1% of them connecting their mySugr app to Bluetooth-enabled glucose meters like Accu-Chek® Guide and Accu-Chek® Instant. These users who connected their meters to the mySugr app were more engaged, automatically recording 90.8 blood glucose values on average, compared to 48.75 for non-connected users. As a part of the analysis of 226 rigorously tracked connected users, eHbA1c levels fell from 7.24% to 6.94% in six months. The percentage of blood glucose readings within the target range (PIR) rose from 69.8% to 75.3%, while those outside the range (Point Above Range or PAR) fell from 28.6% to 23.2%. Connected users had better blood glucose control and more readings within the target range, indicating that the everyday diabetes control improved substantially when using the mySugr app and had a significant positive influence on their diabetes management journey.
Dr. Caterina Pesenti, Medical and Scientific Affairs Lead, IMEA at Roche Diabetes Care stated, "The results of our real-world data analysis undeniably demonstrates the positive impact of integrating the mySugr app with self-monitoring of blood glucose (SMBG) using blood glucose monitoring systems like Accu-Chek Guide or Accu-Chek Instant in the management of Type 2 Diabetes Mellitus. This technology not only improves engagement but also improves glycemic management, thus enhancing the quality of life for people with Type 2 diabetes."
Using mHealth systems, such as the mySugr app in conjunction with self-monitoring of blood glucose (SMBG), helps increase patient participation and achieve better glycemic control. The analysis found that connected users of the mySugr app had a high level of engagement, with a substantial 0.3% drop in eHbA1c with a p-value of 0.01 (indicating a statistical significance). Given the link between a balanced glycemic control and the development of comorbidities, the mySugr app and regular blood glucose monitoring can assist patients in achieving better glycemic control and lowering the incidence of complications while enhancing their quality of life.
About the mySugr® App:
The mySugr® app is a comprehensive diabetes management tool that empowers users to monitor blood glucose levels, track medication intake, log meals, and access personalized insights to make informed decisions about their health. The integration of the Blood Glucose Meter and this user-friendly application has proven to be a game changer for people with T2DM.
About Roche Diabetes Care
Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 4,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines.
Being a global leader in integrated Personalised Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centred value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualising relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments. For better outcomes and true relief.
Since 2017, mySugr, one of the most popular diabetes management apps, is part of Roche Diabetes Care.
For more information, please visit www.rochediabetes.com, www.accu-chek.com and www.mysugr.com.
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For more information please contact:
Cluster Communications Lead
Roche Diabetes Care India, Middle East & Africa
Email: [email protected]